Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study.

J Clin Hypertens (Greenwich) · 2021 · PMC8678714 · PMID 33326172

Europe PMC DOI

hedged sentence

0.0780

closest p · 1.6× alpha

0.0780

boldest claim

The sentences

marginally significantp = .078so close (0.05 < p ≤ 0.1)

−0.28% at week 12, respectively), and there was marginally significant placebo‐subtracted difference between the groups (−0.26% vs. −0.54% at week 12, respectively, p = .078) (Table 2 ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.